What the FDA labels say about taking them together
Fulvestrant and palbociclib
Palbociclib's FDA label of July 2, 2026 names fulvestrant in its warnings and precautions section; the fulvestrant labels PlainMeds reads (3) do not name palbociclib. The palbociclib label: “A Grade ≥3 decrease in neutrophil counts was reported in 66% of patients receiving IBRANCE plus letrozole in PALOMA-2 and 66% of patients receiving IBRANCE plus fulvestrant in PALOMA-3.”
Check it at the source: the fulvestrant FDA label on DailyMed (effective September 25, 2020, AstraZeneca Pharmaceuticals LP); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the fulvestrant label say about palbociclib?
Fulvestrant's label (effective September 25, 2020) and its 2 other brand-application labels do not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (FASLODEX), AstraZeneca Pharmaceuticals LP, effective September 25, 2020 (SPL set 83d7a440-e904-4e36-afb5-cb02b1c919f7), via openFDA; the full label on DailyMed
What does the palbociclib label say about fulvestrant?
Palbociclib label, warnings and precautionsA Grade ≥3 decrease in neutrophil counts was reported in 66% of patients receiving IBRANCE plus letrozole in PALOMA-2 and 66% of patients receiving IBRANCE plus fulvestrant in PALOMA-3.
Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fulvestrant | Palbociclib | |
|---|---|---|
| Labeled for | Breast cancer | Breast cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once